Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Steininger J, Gellrich FF, Schulz A, Westphal D, Beissert S, Meier F. Steininger J, et al. Among authors: westphal d. Cancers (Basel). 2021 Mar 20;13(6):1430. doi: 10.3390/cancers13061430. Cancers (Basel). 2021. PMID: 33804800 Free PMC article. Review.
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F. Niessner H, et al. Among authors: westphal d. Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. doi: 10.1158/1078-0432.CCR-16-0064. Epub 2016 Jun 15. Clin Cancer Res. 2016. PMID: 27307593 Free article.
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F. Niessner H, et al. Among authors: westphal d. Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19. Clin Cancer Res. 2017. PMID: 28724666 Free PMC article.
Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma.
Surowy HM, Giesen AK, Otte J, Büttner R, Falkenstein D, Friedl H, Meier F, Petzsch P, Wachtmeister T, Westphal D, Wieczorek D, Wruck W, Adjaye J, Rütten A, Redler S. Surowy HM, et al. Among authors: westphal d. Br J Dermatol. 2019 May;180(5):1150-1160. doi: 10.1111/bjd.17446. Epub 2019 Jan 20. Br J Dermatol. 2019. PMID: 30472730
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.
Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A. Shannan B, et al. Among authors: westphal d. Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2. Eur J Cancer. 2019. PMID: 30721788
Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.
Müller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D, Meier F, Bachmann M, Schmitz M. Müller L, et al. Among authors: westphal d. Front Immunol. 2020 Feb 5;11:140. doi: 10.3389/fimmu.2020.00140. eCollection 2020. Front Immunol. 2020. PMID: 32117287 Free PMC article. Review.
Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E, Westphal D, Surowy HM, Meier F, Hutter B, Reifenberger J, Rütten A, Schulz A, Sergon M, Ziemer M, Brors B, Betz RC, Redler S. Denisova E, et al. Among authors: westphal d. Cancer Gene Ther. 2022 Jun;29(6):697-708. doi: 10.1038/s41417-021-00347-z. Epub 2021 May 27. Cancer Gene Ther. 2022. PMID: 34045664 Free PMC article.
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Westphal D, Garzarolli M, Sergon M, Horak P, Hutter B, Becker JC, Wiegel M, Maczey E, Blum S, Grosche-Schlee S, Rütten A, Ugurel S, Stenzinger A, Glimm H, Aust D, Baretton G, Beissert S, Fröhling S, Redler S, Surowy H, Meier F. Westphal D, et al. Br J Dermatol. 2021 Dec;185(6):1186-1199. doi: 10.1111/bjd.20604. Epub 2021 Aug 18. Br J Dermatol. 2021. PMID: 34185311
154 results